Federal Register #2026-12842

NCI Seeks Licensees and Research Partners for Dendritic Cell-Based Cancer Vaccine Technology

This opportunity from the National Cancer Institute (NCI), part of the Department of Health and Human Services and the National Institutes of Health, seeks partners for innovative cancer immunotherapy technology. - Government Buyer: - National Cancer Institute (NCI), Department of Health and Human Services, National Institutes of Health - OEMs and Vendors: - National Cancer Institute (NCI) - Products/Services Requested: - Licensing and/or research collaboration for dendritic cell-based cancer vaccine technology - Technology uses omega-3 fatty acids (e.g., DHA, EPA) or specialized pro-resolving lipid mediators to enhance dendritic cell function and anti-tumor efficacy - Intended for therapeutic and research applications in oncology and immunology - No specific part numbers or purchase quantities provided - Licensing of the C816645 human T-cell line - Transformed by HTLV-1, useful for research on viral protein interactions, T-cell immortalization, and HIV replication - Unique or Notable Requirements: - Opportunity is for licensing and research collaboration, not direct product purchase - Technology is in pre-clinical stage with in vivo validation - Focus on improving safety and potency of cancer vaccines - Applications in both therapeutic development and basic research

Description

The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI's compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. These vaccines are improved by generating dendritic cells in the presence of omega-3 fatty acids and their derivatives to restore and enhance antigen-presenting function and anti-tumor efficacy. This approach aims to overcome limitations in current cancer immunotherapies by improving vaccine potency and safety. The technology is in the pre-clinical stage with in vivo validation.

View original listing